Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 1997

View Archived Issues

Epilepsy monotherapy approved in Canada

Endothelin antagonist protects against indomethacin-induced gastric damage

New hypoglycemic/insulin-sensitizing agent from Novartis

PN-401: a new uridine prodrug from Pro-Neuron

TIMI-IIA finds enoxaparin promising

Modified t-PA from Eisai highly effective thrombolytic

Lidocaine/prilocaine cream effective and safe in neonatal circumcision

MS-322: new centrally acting muscle relaxant with little CNS depressant activity

Neuroprotective effects of NMDA antagonists in animal models

ReoPro safe and effective in high-risk PTCA patients

YM-435 shows promise in acute hypertensive episodes

JTV-506: a potent and selective coronary vasodilator from Japan Tobacco

Preclinical results with Anika's INCERT promising

MDX-210 shows promise in advanced kidney and prostate cancer

Recombinant multiantigen AIDS vaccine enters second phase I trial

Abbott and Metabolex enter diabetes collaboration

DynaGen acquires Superior Pharmaceutical

Cellegy's antiwrinkling product enters clinical trials

Trega Biosciences and Ono to collaborate on melanocortin receptor pathway research

Sequus signs marketing agreement for Amphocil

Schering-Plough and Chiroscience to collaborate on asthma and inflammatory disease treatments

Genzyme and Massachusetts General Hospital to collaborate on gene therapy projects

Algene and Janssen extend collaboration in genetic study of schizophrenia

Cell Genesys reports encouraging preclinical results of gene therapy for hemophilia

Catalytica to acquire Glaxo Wellcome pharmaceutical production facility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.